Cognate beefs up cell, gene therapy manufacturing with new plants in U.S., EU

SourceFIERCE Pharma
Date Published01/22/2021
Author NameFraiser Kansteiner
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Cognate BioServices
Type of work Manufacturing
If manufacturing, is the company a contract manufacturer?Yes
Reshoring category:Reshoring
Total number of jobs (added or to be added):500
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2021
City reshored to:Memphis
State(s) reshored to:TN
If relevant, work nearshored to:-
Product(s) reshoredcell therapies, advanced therapies, gene therapies
What domestic positive factors made reshoring more attractive?Under-utilized capacity
Find Reshoring Articles